354 Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study

Title
354 Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue Suppl 2, Pages A381-A381
Publisher
BMJ
Online
2021-11-09
DOI
10.1136/jitc-2021-sitc2021.354

Ask authors/readers for more resources

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started